News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.
The grant was awarded through the Alzheimer's Drug Discovery Foundation's Diagnostic Accelerator, a partnership between the charity and philanthropic partners.
Two new grants are helping the company develop its SHERLOCK and INSPECTR technologies as the basis for creating innovative diagnostics.
The company said its test is faster, more precise, and cheaper than the current gold standard Cepheid GeneXpert test.
The blood-based test is designed to detect changes in levels of microRNAs that are enriched in specific brain regions affected by Alzheimer's disease.
The companies also launched an early-access program for their first CRISPR-Chip-based product, the Genome Sensor.